Angiopoietin-2: Development of inhibitors for cancer therapy

Current Oncology Reports

Volumn 11, Issue 2, 2009, Pages 111-116

  Hu, Bo ^b   Cheng, Shi Yuan ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN 2 ANTIBODY; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; DRUG RESEARCH; DRUG TARGETING; HUMAN; LYMPHANGIOGENESIS; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; HUMANS; INTEGRINS; LYMPHANGIOGENESIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION;

EID: 60349121010     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0017-3     Document Type: Review

References (49)

1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
2. Shim WS,AHo IA, Wong PE: Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007, 5:655-665.
3. Davis S, Aldrich TH, Jones PF, et al.: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [see comments]. Cell 1996, 87:1161-1169.
4. Suri C, Jones PF, Patan S, et al.: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comments]. Cell 1996, 87:1171-1180.
5. Suri C, McClain J, Thurston G, et al.: Increased vascularization in mice overexpressing angiopoietin-1. Science 1998, 282:468-471.
6. Thurston G, Suri C, Smith K, et al.: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514.
7. Maisonpierre PC, Suri C, Jones PF, et al.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comments]. Science 1997, 277:55-60.
8. Holash J, Maisonpierre PC, Compton D, et al.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
9. Lobov IB, Brooks PC, Lang RA: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002, 99:11205-11210.
10. Gale NW, Thurston G, Hackett SF, et al.: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002, 3:411-423.
11. Dellinger M, Hunter R, Bernas M, et al.: Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol 2008, 319:309-320.
12. Rao S, Lobov IB, Vallance JE, et al.: Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development 2007, 134:4449-4458.
13. Jones N, Nljin K, Dumont DJ, et al.: Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001, 2:257-267.
14. Scharpfenecker M, Fiedler U, Reiss Y, et al.: The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005, 118:771-780.
15. Hildbrand P, Cirulli V, Prinsen RC, et al.: The role of angiopoietins in the development of endothelial cells from cord blood CD34+ progenitors. Blood 2004, 104:2010-2019.
16. Lemieux C, Maliba R, Favier J, et al.: Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005, 105:1523-1530.
17. Tait CR, Jones PF: ATgiopoietins in tumours: the angiogenic switch. J Pathol 2004, 204:1-10.
18. Cao Y, Sonveaux P, Liu S, et al.: Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007, 67:3835-3844.
19. Lee OH, Fueyo J, Xu J, et al.: Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 2006, 8:419-428.
20. Bach F, Uddin FJ, Burke D: Angiopoietins in malignancy. Eur J Surg Oncol 2007, 33:7-15.
21. Imanishi Y, Hu B, Jarzynka MJ, et al.: Angiopoietin-2 stimulates breast cancer metastasis through the {alpha}5{beta}1 integrin-mediated pathway. Cancer Res 2007, 67:4254-4263.
22. Guo P, Imanishi Y, Cackowski FC, et al.: Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 2005, 166:877-890.
23. Hu B, Guo P, Fang Q, et al.: Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 2003, 100:8904-8909.
24. Eklund L, Olsen BR: Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006, 312:630-641.
25. Kanda S, Miyata Y, Mochizuki Y, et al.: Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res 2005, 65:6820-6827.
26. Cho CH, Kim KE, Byun J, et al.: Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res 2005, 97:86-94.
27. Harfouche R, Hussain SN: Signaling and regulation of endothelial cell survival by angiopoietin-2. Am J Physiol 2006, 291:H1635-H1645.
28. Lee OH, Xu J, Fueyo J, et al.: Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene 2008, 27:1310-1314.
29. Yancopoulos GD, Davis S, Gale NW, et al.: Vascularspecific growth factors and blood vessel formation. Nature 2000, 407:242-248.
30. Carlson TR, Feng Y, Maisonpierre PC, et al.: Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001, 276:26516-26525.
31. Dallabrida SM, Ismail N, Oberle JR, et al.: Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res 2005, 96:e8-e24.
32. Davis S, Papadopoulos N, Aldrich TH, et al.: Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 2003, 10:38-44.
33. Weber CC, Cai H, Ehrbar M, et al.: Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization. J Biol Chem 2005, 280:22445-22453.
34. Cascone I, Napione L, Maniero F, et al.: Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J Cell Biol 2005, 170:993-1004.
35. Hu B, Jarzynka MJ, Guo P, et al.: Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the {alpha}v{beta}1 integrin and focal adhesion kinase signaling pathway. Cancer Res 2006, 66:775-783.
36. Wu Y, Chen L, Zheng PS, et al.: Beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PGM/versican. J Biol Chem 2002, 277:12294-12301.
37. Phelps ED, Updike DL, Bullen EC, et al.: Transcriptional and posttranscriptional regulation of angiopoietin-2 expression mediated by IGF and PDGF in vascular smooth muscle cells. Am J Physiol Cell Physiol 2006, 290:C352-C361.
38. Kim I, Kim JH, Ryu YS, et al.: Tumor necrosis factor-alpha upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2000, 269:361-365.
39. Huang YQ, Li JJ, Hu L, et al.: Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002, 99:1646-1650.
40. Ye F, Florian M, Magder SA, et al.: Regulation of angiopoietin and Tie-2 receptor expression in non-reproductive tissues by estrogen. Steroids 2002, 67:305-310.
41. Cohen B, Barkan D, Levy Y, et al.: Leptin induces angiopoietin-2 expression in adipose tissues. J Biol Chem 2001, 276:7697-7700.
42. Yao D, Taguchi T, Matsumura T, et al.: High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 2007, 282:31038-31045.
43. Potente M, Urbich C, Sasaki K, et al.: Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 2005, 115:2382-2392.
44. Xue Y, Cao R, Nilsson D, et al.: FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci U S A 2008, 105:10167-10172.
45. Schliemann C, Bieker R, Thoennissen N, et al.: Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007, 21:1901-1906.
46. Scholz A, Rehm VA, Rieke S, et al.: Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 2007, 102:2471-2481.
47. Park JH, Park KJ, Kim YS, et al.: Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007, 132:200-206.
48. White RR, Shan S, Rusconi CP, et al.: Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A 2003, 100:5028-5033.
49. Oliner J, Min H, Leal J, et al.: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.